Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • EHA 2026

European Hematology Association

June 11 - 14, 2026

  1. All
  2. Acalabrutinib
  3. Surovatamig (AZD0486)
  4. AZD0120
  5. AZD3470
  6. AZD3632
  7. Oncology Unbranded

PDF

Final Results From ASSURE: A Phase 3b Study of the Safety and Efficacy of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

PDF

Quality of Life and Symptoms With Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs Chemoimmunotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: Patient-Reported Outcomes From AMPLIFY

PDF

Safety of Fixed-Duration (FD) Acalabrutinib-Venetoclax Combinations in Patients (Pts) With Chronic Lymphocytic Leukemia (CLL) Stratified by Age: Post Hoc Analysis of the Phase 3 AMPLIFY Trial

PDF

Incidence of Infections in Patients Treated With Rituximab-Bendamustine With or Without Acalabrutinib for Untreated Mantle Cell Lymphoma: Analysis of the Phase 3 ECHO Trial

PPT

Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma (FL): Initial Safety Data from the Phase 3 SOUNDTRACK-F1 Trial

PPT

AZD0120, A Dual BCMA/CD19 CAR-T Cell Therapy, Demonstrates a Naive/Central Memory Phenotype and Induces a Rapid Decline in Soluble BCMA in Relapsed/Refractory Multiple Myeloma

PDF

A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA)

PDF

Transcriptional rewiring to a monocytic state reveals therapeutic vulnerabilities in Menin inhibitor resistance AML

PDF

Real‑world characteristics, treatment patterns, and outcomes of newly diagnosed diffuse large B‑cell lymphoma (DLBCL) patients treated in first-line (1L) in the United States (US) community oncology setting

PDF

Final Results From ASSURE: A Phase 3b Study of the Safety and Efficacy of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

PDF

Quality of Life and Symptoms With Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs Chemoimmunotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: Patient-Reported Outcomes From AMPLIFY

PDF

Safety of Fixed-Duration (FD) Acalabrutinib-Venetoclax Combinations in Patients (Pts) With Chronic Lymphocytic Leukemia (CLL) Stratified by Age: Post Hoc Analysis of the Phase 3 AMPLIFY Trial

PDF

Incidence of Infections in Patients Treated With Rituximab-Bendamustine With or Without Acalabrutinib for Untreated Mantle Cell Lymphoma: Analysis of the Phase 3 ECHO Trial

PPT

Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma (FL): Initial Safety Data from the Phase 3 SOUNDTRACK-F1 Trial

PPT

AZD0120, A Dual BCMA/CD19 CAR-T Cell Therapy, Demonstrates a Naive/Central Memory Phenotype and Induces a Rapid Decline in Soluble BCMA in Relapsed/Refractory Multiple Myeloma

PDF

A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA)

PDF

Transcriptional rewiring to a monocytic state reveals therapeutic vulnerabilities in Menin inhibitor resistance AML

PDF

Real‑world characteristics, treatment patterns, and outcomes of newly diagnosed diffuse large B‑cell lymphoma (DLBCL) patients treated in first-line (1L) in the United States (US) community oncology setting

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States